July/August #189 : Viral Suppression Without Drugs? - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Magnetic Attraction

A Shred of Understanding

Hold Your Horses

From the Editor

Accentuate the Positive


Letters-July/August 2013


Pride and Policy

POZ Planet

Say What?—Alicia Keys

Greetings from Ptown

PACHA Covers Trans Issues

Making Headlines

Latest Developments

Not Another Gay Sex Disease

Future Lovers

On a Roll


Yours in the Struggle

Care and Treatment

The Quest to Cure Another Baby

Viral Suppression Without Drugs?

The Genetic Fusion Inhibitor

New Retention Guidelines Urge Partnerships

Mapping Viral and Immune Coevolution

Research Notes

Prevention: PrEP May Be Cost-Effective

Treatement: Can Bees Sting Away HIV?

Cure: HDAC Inhibitors May Fight HIV Reservoir

Concerns: Hep C Transmission Among Gay Men

POZ Survey Says

Accentuate the Negative

POZ Heroes

Chemical Crusader

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July / August 2013

Viral Suppression Without Drugs?

by Benjamin Ryan

Fourteen French people who started treatment within two months of contracting HIV have all kept their virus under control after stopping antiretroviral (ARV) therapy, achieving what researchers are calling a “viral remission.” The 10 men and four women were treated for between one and 7.6 years, with a median length of three years. They have remained off therapy for between four and 9.6 years. Eleven of them have maintained viral loads below 50 (considered undetectable) and three below 400.  

Adding another layer to the increasingly detailed argument supporting the benefits of early therapy, the French investigators estimate that perhaps as many as 15 percent of people who begin HIV treatment shortly after infection may also experience such viral remission if they eventually stop taking ARVs.

While public perception has suggested that each of these cases is an example of a “functional cure”—implying the virus has been all but eradicated, and permanently so—the French investigators were more measured in their assessment at this point.

“This is proof of principle that we can induce this state of HIV remission in a group of patients who were not predisposed to do so naturally,” says the study’s lead author, Asier Sáez-Cirión, PhD, of the Institut Pasteur in Paris.

His team is participating in a new clinical trial to study how two years of a pair of differing ARV regimens will impact the viral reservoir and the control of infection after a treatment interruption.

Search: antiretroviral therapy, viral remission, clinical trial

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.